This protocol is for patients with indolent (ISM) or smoldering (SSM) systemic mastocytosis who experience gastrointestinal symptoms driven by their disease. Treatment in this setting is primarily directed toward symptom control and anaphylaxis prevention.
DOI: 10.1002/ajh.26962
Treatment goals for ISM patients are primarily directed toward anaphylaxis prevention/symptom control/osteoporosis treatment.
100–200 mg QID 30 min before meals and bedtime
View source ↗